



RESVERLOGIX (TSX:RVX) IS A LATE-STAGE BIOTECHNOLOGY COMPANY WITH A NOVEL EPIGENETIC APPROACH TO REDUCING THE INCIDENCE OF MAJOR ADVERSE CARDIAC EVENTS (MACE) IN HIGH-RISK CARDIOVASCULAR PATIENTS. LEAD DRUG APABETALONE IS FULLY ENROLLED IN A PHASE 3 CLINICAL TRIAL CALLED BETONMACE.

Resverlogix is developing safe, affordable, first-in-class epigenetic therapeutics for people with heart disease, diabetes, chronic kidney disease and other life-threatening illnesses. Lead drug candidate **apabetalone** is in a fully enrolled **Phase 3 clinical trial, BETonMACE**. Topline data is estimated for Q1 2019.



MULTI-MODAL PATHWAY MECHANISM

Apabetalone, a bromodomain extra-terminal (BET) protein inhibitor regulates the expression of genes and restores the function of pathways underlying the pathogenesis of **cardiovascular disease, type 2 diabetes mellitus and chronic kidney disease**.




✉ : ir@resverlogix.com
 ☎ : 403.254.9252
 🌐 : www.resverlogix.com
 🐦 : @Resverlogix_RVX



TSX:
RVX

CHROMOSOME CHROMATIN FIBRE NUCLEOSOME



EPIGENETICS

A mechanism for regulating gene activity independent of DNA sequence that determines which genes are turned on or off:

- o in a particular cell type
- o in different disease states
- o in response to a physiological stimulus

COPYRIGHT © 2012 - RICHARD E. BALLERMANN


Epigenetics

While most people are familiar with the inheritance of genes via DNA from one generation to the next, the activity of these genes is actually determined by epigenetics, which literally means "on top of" genetics. DNA is considered the hardware of the human body, while epigenetics can be referred to as the software. DNA contains the code that tells our cells what to do, and this coded message is the same in every cell and does not change with time. However, our cells do not behave in the exact same way across time, particularly when disease is involved. Epigenetic changes to the DNA allow the message in the genes to be turned up or down like a dimmer switch, telling the cells which products to make more, or less of. During this process the DNA is not altered. The epigenetic control over the genetic message in the DNA underlies many diseases, and for this reason, epigenetics has become an exciting forefront for the discovery of new medicines.

APABETALONE (RVX-208) CLINICAL TRIAL HISTORY

Completed Trials

Current and Planned Trials



- Phase 3 BETonMACE trial commenced Q4/15 for high-risk CVD patients with type 2 diabetes mellitus and low HDL. ~15% of the patients will also have CKD. BETonMACE is fully enrolled.
- Primary endpoint: time to first occurrence of Major Adverse Cardiac Events (MACE).
- Based on mechanistic data, we believe apabetalone treatment, or select BET inhibition, attenuates the pathological process that contributes to disease initiation and progression.

News Highlights

Oct. 22, 2018 - RVX announces participation at premier kidney, Alzheimer's disease, and cardiovascular conferences

Sept. 4, 2018 - RVX presents at CTAD Asia

Aug. 30, 2018 - RVX closes \$26 million private placement

Future Events

Nov. 11-12: AHA Scientific Sessions 2018, Chicago, IL
- Two poster presentations - more info [HERE](#)

Analysts

Beacon Securities: David M. Kideckel, PhD, MBA.

Roth Capital Partners: Jotin Marango, MD, PhD.

Van Leeuwenhoeck Research: Marcel Wijma, MSc.

Zacks: John Vandermosten, CFA.

Financial Profile

- Shares O/S (MM): 188.5
- Share Price: \$3.27
- Market Cap (MM): ~\$626
- 52 week low/high: \$1.11/\$4.31
- Total Cash Raised (MM): ~\$449

Notes:

*As at 30-OCT-18

*All figures in CAD\$